FGFR2 and colorectal carcinoma: This study aimed to evaluate the therapeutic potential of combining FGFR inhibitors with CBD, investigate the underlying molecular mechanisms—focusing on ER stress pathways—and assess whether this combination can elicit a synergistic antitumor effect in FGFR2-overexpressing CRC cells.